Literature DB >> 28224327

Effects of in vivo and in vitro administration of neuro-Behcet's disease IgG.

Ece Erdağ1, Ceren Şahin2, Cem İsmail Küçükali1, Sinem Bireller3, Melike Küçükerden1, Murat Kürtüncü4, Recai Türkoğlu5, Bedia Cakmakoglu3, Erdem Tüzün6, Feyza Arıcıoğlu2.   

Abstract

Antibodies directed against membrane antigens of neuronal axonal processes (neuropil) have been recently identified in neuro-Behcet's disease (NBD) patients. To delineate the potential pathogenic action of these antibodies, pooled sera from seven NBD patients with neuropil antibodies and seven healthy controls were divided into purified IgG and IgG-depleted serum (IgG-DS) fractions and each fraction was administered into lateral ventricles of rats. NBD IgG-injected rats showed reduced locomotor activity in the open field test as compared to NBD IgG-DS, healthy control IgG, healthy control IgG-DS and PBS injected rats (n = 10 for each group). There were no significant differences among treatment groups by means of anxiety-like behaviors (assessed by elevated plus maze test) and learning/memory functions (assessed by passive avoidance test). Administration of NBD IgG on cultured SH-SY5Y neuroblastoma cells induced significantly increased cell death and apoptosis (as measured by nucleosome levels in the supernatants) as compared to other treatment groups. Our results suggest that IgGs isolated from sera of neuropil antibody-positive NBD patients have a neurotoxic action, which is presumably mediated by apoptotic mechanisms. Motor deficits frequently observed in NBD patients might at least partially be caused by the pathogenic action of anti-neuronal IgG.

Entities:  

Keywords:  Apoptosis; Behcet’s disease; IgG; Locomotor activity; Neuro-Behcet’s disease

Mesh:

Substances:

Year:  2017        PMID: 28224327     DOI: 10.1007/s10072-017-2856-2

Source DB:  PubMed          Journal:  Neurol Sci        ISSN: 1590-1874            Impact factor:   3.307


  27 in total

1.  Intravenous immunoglobulin therapy for resistant ocular Behçet's disease.

Authors:  N Seider; I Beiran; J Scharf; B Miller
Journal:  Br J Ophthalmol       Date:  2001-11       Impact factor: 4.638

2.  Human N-methyl D-aspartate receptor antibodies alter memory and behaviour in mice.

Authors:  Jesús Planagumà; Frank Leypoldt; Francesco Mannara; Javier Gutiérrez-Cuesta; Elena Martín-García; Esther Aguilar; Maarten J Titulaer; Mar Petit-Pedrol; Ankit Jain; Rita Balice-Gordon; Melike Lakadamyali; Francesc Graus; Rafael Maldonado; Josep Dalmau
Journal:  Brain       Date:  2014-11-11       Impact factor: 13.501

Review 3.  Criteria for diagnosis of Behçet's disease. International Study Group for Behçet's Disease.

Authors: 
Journal:  Lancet       Date:  1990-05-05       Impact factor: 79.321

4.  Clinical patterns of neurological involvement in Behçet's disease: evaluation of 200 patients. The Neuro-Behçet Study Group.

Authors:  G Akman-Demir; P Serdaroglu; B Tasçi
Journal:  Brain       Date:  1999-11       Impact factor: 13.501

Review 5.  Humoral autoimmunity in multiple sclerosis.

Authors:  Edgar Meinl; Tobias Derfuss; Markus Krumbholz; Anne-Katrin Pröbstel; Reinhard Hohlfeld
Journal:  J Neurol Sci       Date:  2010-09-03       Impact factor: 3.181

Review 6.  B cell-directed therapies in multiple sclerosis.

Authors:  Christiane Gasperi; Olaf Stüve; Bernhard Hemmer
Journal:  Neurodegener Dis Manag       Date:  2016

7.  Paraneoplastic anti-Hu serum: studies on human tumor cell lines.

Authors:  J J Verschuuren; J Dalmau; R Hoard; J B Posner
Journal:  J Neuroimmunol       Date:  1997-11       Impact factor: 3.478

8.  Humoral immune response to mycobacterial heat shock protein (hsp)65 in the cerebrospinal fluid of neuro-Behçet patients.

Authors:  B Taşçi; H Direskeneli; P Serdaroglu; G Akman-Demir; M Eraksoy; G Saruhan-Direskeneli
Journal:  Clin Exp Immunol       Date:  1998-07       Impact factor: 4.330

9.  Rituximab is effective in severe treatment-resistant neurological Behçet's syndrome.

Authors:  D P Kidd
Journal:  J Neurol       Date:  2015-09-26       Impact factor: 4.849

10.  Mitochondrial carrier homolog 1 (Mtch1) antibodies in neuro-Behçet's disease.

Authors:  Burçak Vural; Elçin Sehitoğlu; Filiz Cavuş; Nazlı Yalçınkaya; Hazal Haytural; Melike Küçükerden; Canan Ulusoy; Elif Uğurel; Selin Turan; Leyla Bulut; Recai Türkoğlu; Erkingül Shugaiv; Murat Kürtüncü; Sükrü Atakan; Ali O Güre; Ahmet Gül; Mefkure Eraksoy; Gülşen Akman-Demir; Erdem Tüzün
Journal:  J Neuroimmunol       Date:  2013-08-24       Impact factor: 3.478

View more
  2 in total

1.  Past and Present Behçet's Disease Animal Models.

Authors:  Jermilia Charles; Francis J Castellino; Victoria A Ploplis
Journal:  Curr Drug Targets       Date:  2020       Impact factor: 3.465

2.  Auto-immunity profile evaluation during different clinical manifestations of Behçet disease in Algerian patients: effect of corticosteroid treatment.

Authors:  Fatmazohra Djaballah-Ider; Abdelhamid Djaballah; Zineb Djeraba; Samia Chaib; Chafia Touil-Boukoffa
Journal:  Inflammopharmacology       Date:  2019-02-05       Impact factor: 4.473

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.